Exagen (NASDAQ:XGN) CEO John Aballi Sells 15,698 Shares of Stock

Exagen Inc. (NASDAQ:XGN) CEO John Aballi sold 15,698 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $3.62, for a total value of $56,826.76. Following the sale, the chief executive officer owned 687,299 shares in the company, valued at approximately $2,488,022.38. The trade was a 2.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

John Aballi also recently made the following trade(s):

• On Tuesday, February 24th, John Aballi sold 11,430 shares of Exagen stock. The shares were sold at an average price of $3.61, for a total transaction of $41,262.30.

Exagen Trading Down 13.1%

NASDAQ:XGN traded down $0.47 during trading hours on Thursday, hitting $3.12. The company had a trading volume of 416,329 shares, compared to its average volume of 522,380. The company has a 50-day moving average of $4.46 and a 200 day moving average of $7.73. The company has a market cap of $70.70 million, a P/E ratio of -3.39 and a beta of 1.88. The company has a current ratio of 4.08, a quick ratio of 4.08 and a debt-to-equity ratio of 1.35. Exagen Inc. has a 1 year low of $2.77 and a 1 year high of $12.23.

Analyst Ratings Changes

Several brokerages recently weighed in on XGN. BTIG Research reduced their target price on shares of Exagen from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. B. Riley Financial reaffirmed a “buy” rating and set a $8.00 price objective (down from $18.00) on shares of Exagen in a research report on Friday, January 30th. TD Cowen cut their price target on Exagen from $13.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, February 24th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Exagen in a research note on Wednesday, January 21st. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $11.43.

Hedge Funds Weigh In On Exagen

Several hedge funds have recently bought and sold shares of the stock. Bridgeway Capital Management LLC lifted its position in shares of Exagen by 10.3% in the second quarter. Bridgeway Capital Management LLC now owns 27,800 shares of the company’s stock valued at $194,000 after acquiring an additional 2,600 shares in the last quarter. Calamos Advisors LLC grew its holdings in shares of Exagen by 3.5% during the third quarter. Calamos Advisors LLC now owns 78,090 shares of the company’s stock worth $858,000 after buying an additional 2,677 shares in the last quarter. Truvestments Capital LLC lifted its stake in shares of Exagen by 109.5% during the fourth quarter. Truvestments Capital LLC now owns 6,169 shares of the company’s stock valued at $38,000 after buying an additional 3,225 shares during the period. State Street Corp boosted its position in Exagen by 6.9% during the fourth quarter. State Street Corp now owns 71,256 shares of the company’s stock worth $433,000 after acquiring an additional 4,600 shares during the last quarter. Finally, Huntleigh Advisors Inc. grew its stake in Exagen by 6.3% in the 3rd quarter. Huntleigh Advisors Inc. now owns 93,353 shares of the company’s stock worth $1,026,000 after acquiring an additional 5,492 shares during the period. Hedge funds and other institutional investors own 75.25% of the company’s stock.

Exagen Company Profile

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.